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Levodopa (LD) is the gold standard for the treatment of Parkinson’s disease (PD). Genetic polymorphisms in the SLC6A3 
gene (Solute carrier family 6 member 3/DAT-Dopamine Transporter gene) are shown to have a functional impact on 
levodopa therapeutic response, motor complications of PD and adverse events. Hence the present study was carried out to 
investigate the association of SLC6A3 polymorphisms with the pharmacokinetics of levodopa and clinical response. A total 
of 150 PD patients were recruited in the study. Plasma levodopa was analysed by HPLC at 0, 1, 2, 3 and 4 h post levodopa 
administration and AUC was calculated. Genotyping of SLC6A3 40 bp VNTR and SLC6A3 rs393795 (G>T) 
polymorphisms was done by the PCR-RFLP method. The result shows that AUC of levodopa was significantly higher in 
patients carrying homozygous10/10 genotype (P =0008) compared to 9/9 genotype of SLC6A3 40 bp VNTR 
polymorphism. A similar difference was also observed in early-onset Parkinson’s disease (EOPD) and late-onset 
Parkinson’s disease (LOPD) groups. SLC6A310/10 genotype was found to be significantly associated with disease severity 
(P =0.05) compared with the 9/10 genotype in the EOPD group, however, there was no significant association with 
dyskinesia. To conclude, patients carrying SLC6A3 40VNTR 10/10 genotype were found to have higher levodopa exposure, 
disease severity and prone to further neurodegeneration.  
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Parkinson’s disease (PD) is the second most common 
neurodegenerative disorders and it is caused by the 
depletion of dopamine (DA) producing neurons in the 
basal ganglia in the brain1 resulting in the cardinal 
motor symptoms such as bradykinesia (slowness of 
movements), tremor (shaking) and rigidity (stiffness). 
Clinical diagnosis of PD is based on at least two of 
the three cardinal motor symptoms with the 
asymmetrical onset and a positive response to 
levodopa or DA agonists. Several factors affect the 
bioavailability of levodopa and its therapeutic 
response. Levodopa is the standard drug of choice for 
the treatment of Parkinson's disease (PD) because of 
its remarkable clinical efficacy. However, various 
adverse events, including wearing-off phenomenon, 
the on-off phenomenon, dyskinesia, and psychiatric 
symptoms are experienced by the majority of the 
patients. The response to levodopa depends on 
various factors including the type of levodopa 
preparation, its absorption/metabolism, the blood-
brain barrier, age at onset of disease, concomitant use 
of anti-parkinsonian drugs and the intrinsic 
responsiveness of the patients which include pre- and 
postsynaptic dopamine receptors2. 
When levodopa is administered systemically, 
whether oral or intravenous, some levodopa in the 
peripheral system (Fig. 1) undergoes decarboxylation 
by aromatic amino acid decarboxylase (AADC/DDC) 
and gets converted to dopamine which does not cross 
the blood-brain barrier3,4. Some of the administered 
levodopa is metabolised peripherally by catechol-O-
methyltransferase (COMT) and converted to 3-O-
methyldopa (3-OMD), which does not work as a 
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dopaminergic neurotransmitter in the striatum5. The 
remaining levodopa crosses the blood-brain barrier, 
gets converted into dopamine by AADC, stored as 
dopamine in the synaptic vesicles by vesicular 
monoamine transporter-2 (VMAT-2), metabolized, 
released, and reuptake mainly by dopaminergic 
neurons, the normal striatum6. Dopamine transporters 
(DAT/SLC6A3) are expressed at terminals of 
dopaminergic neurons and reuptake extracellular 
dopamine for reuse or metabolization7-12. The 
negative feedback by D2 dopamine receptors and with 
SLC6A312, dopaminergic neurons controls the 
extracellular dopamine levels. 
The functional polymorphisms of genes involving 
in the above process may have an impact on the 
therapeutic response of levodopa. In a recent study, it 
was observed that chronic high-dose (1 mg/kg/day) 
methylphenidate (an inhibitor of SLC6A3) administration 
reduced the severity of gait disorders in patients with 
advanced Parkinson’s disease13 which indicates that 
pharmacogenetic factors may be partly responsible for 
the heterogeneity of methylphenidate therapeutic 
response. In another study, SLC6A3 was found to be 
the most powerful determinant of dopamine 
neurotransmission14. The genetic studies further 
reveal that the 9- and 10-repeat alleles are the most 
frequent in patients with PD15. In this study, we 
therefore, investigated the association of genetic 
polymorphisms in SLC6A3 with levodopa 
pharmacokinetics and a functional impact on 
levodopa therapeutic response and adverse events in 
patients with PD. 
Materials and Methods 
Study subjects  
We recruited 150 Parkinson’s disease patients 
visiting the Department of Neurology at Nizam’s 
Institute of Medical Sciences (NIMS), Hyderabad, 
India. Patients who had secondary Parkinson’s 
disease (drug-induced), atypical Parkinsonian 
syndromes and other neurological disorders were 
excluded from the study. All the patients were 
recruited based on UK Parkinson’s disease society 
brain bank clinical criteria (exclusion criteria of 
familial PD was not considered) for the diagnosis of 
PD. Baseline characteristics such as gender, age, 
height, weight, body mass index, disease duration, 
age at onset of all of the patients were obtained using 
a self-designed questionnaire and medical records. 
The data of levodopa (represents combination of 
levodopa and carbidopa in 1:4 ratio) response by 
Unified Parkinson's Disease Rating Scale part III 
(UPDRS – III) in OFF (12 h without dopaminergic 
medication)–ON scores (best response after 
levodopa challenge i.e., approx 1 h after 250 mg 
levodopa), cognition by MoCA (Montreal Cognitive 
Assessment), disease severity by modified Hoehn 
and Yahr scale (H & Y) Scoring, and activity of 
daily living by Schwab and England (S & E) were 
collected using standard questionnaire. This study 
was approved by the Institutional Ethics Committee 
(NIEC) of Nizam’s Institute of Medical Sciences 
(EC/NIMS/1895(a)/2017) Hyderabad, India. The 
informed consent was obtained from all the subjects 
and from the patient’s guardians those who unable to 
give the consent 
 
Sample collection 
For the estimation of plasma levodopa, 3 mL blood 
sample was collected in the fasting condition after 
overnight withdrawal of L-DOPA and 24 h of 
withdrawal of dopaminergic agonists and at 0, 1, 2,  
3 and 4th h after the levodopa (250 mg) 
administration. Blood was subjected to centrifugation 
at 3000 rpm for 10 min for the separation of plasma at 
4C. These plasma samples were aliquoted and stored 
at −20C after adding 50 µL of 10% sodium 
metabisulphite (for the stability of levodopa) per  
1 mL of plasma. Genomic DNA was extracted from 
whole blood using the standard phenol–chloroform 
extraction protocol. 
 
 
Fig. 1 — Dopamine Metabolism showingreuptake of DA from 
synaptic cleft into presynaptic neuron. D2/D3 – Dopamine 
receptor 2/3, DAT – Dopamine transporter (SLC6A3), COMT –
Catechol O methyl Transferase, MAO-B – Monoamine oxidase B  
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Pharmacokinetic (PK) analysis of Levodopa 
Chemicals and reagents 
L-DOPA and Methyl-L-DOPA were purchased 
from Sigma Aldrich. Acetonitrile and methanol used 
were HPLC grade and obtained from Fisher Scientific. 
All other chemicals used were analytical grade. 
 
Levodopa estimation by HPLC 
The Shimadzu HPLC with Fluorescence Detector 
(Prominence series) was used for the estimation of 
plasma levodopa concentrations. The chromatographic 
analysis was performed using the KINETEX column 
(250×4.6 mm) with particle size of 5 µM analytical 
column, isocratic mobile phase consisted of 10 mM 
Potassium Hydrogen Phosphate (KH2PO4) (pH 3.5) 
and methanol (HPLC grade) (95:5, v/v) at flow rate of 
0.4 mL/min for 25 min. The absorbance of L-Dopa 
and Me-Dopa was monitored using fluorescence 
detector at excitation 270 nm and emission 320 nm 
and retention time (RT) at 8 min and 12 min, 
respectively16 (Fig. 2). The Cmax and time to reach 
Cmax i.e., Tmax  were obtained directly from the 
individual plasma–concentrationtime data for 
levodopa. The area under concentration–time curve 
from time zero to 4 h (AUC0–4 h) was measured 
using linear trapezoidal summation with extrapolation17. 
 
Genomic DNA isolation 
Genomic DNA was extracted from whole blood 
using the standard phenol–chloroform extraction 
protocol. 
 
Genotyping of SLC6A3 40 bp repeat polymorphism IN 3-UTR 
Genotyping of 40 bp-VNTR polymorphism in 3-
UTR region was determined by using standard PCR 
protocol and the primers used are (i) SLC6A3 forward 
primer: 5-TGTGGTGTAGGGAACGGCCTGAGA-
3 and (ii) SLC6A3 reverse primer: 5- TGTTGG 
TCTGCAGGCTGCCTGCAT-3 . Ten microliter 
volume was used for each PCR reaction, containing 2 
pico mole/μL of each primer, 5 µL of Takara Emerald 
Amp GT polymerase chain reaction (PCR) master 
mix, together with 3–4 µL of 50 ng/µL genomic DNA 
using Eppendorf master cycler. PCR conditions for the 
amplification were as follows: initial denaturation at 
94C for 5 min, followed by 40 cycles of 30 sec at 94C,  
15 s at 61.5C and 45 sec at 72C for an extension, and a 
final extension of 10 min at 72C. The amplified PCR 
fragments were run on 3% agarose gel and were 
visualized using an ultraviolet transilluminator for 
genotyping. The lowquality PCR products were 
subjected to reanalysis. The ten copies of 40 bp 
repeats (10R) generating a 476 bp band, nine copies 
of 40 bp repeats (9R) generating a 436 bp band, eight 
copies of 40 bp repeats (8R) generating a 396 bp 
band, seven copies of 40 bp repeats (7R) generating a 
356 bp band, six copies of 40 bp repeats (6R) 
generating a 316 bp band, and five copies of 40 bp 
repeats (5R) generating a 276 bp band (Fig. 3A) 18.  
 
Fig 2 — Estimation of plasma levadopa by reverse-phase HPLC
Chromatogram depicts Levodopa and internal standard, methyl 
DOPA. The retention time (RT) of Levadopa is at 8 min and 
methyl DOPA at 12 min, respectively 
 
 
Fig. 3 —(A) Representative gel image of SLC6A3 polymorphism 
(40 bp VNTR) PCR Product checked on Gel electrophoresis. 
Lanes 1, 4, 5, 11- 5/5(276 bp, Lanes 2, 3, 6, 7, 8, 9 – 10/10 (476 
bp), Lane 10 – 9/10 (436 bp), Lane 12 – 7/7 (356 bp), Lane 13- 50 
bp DNA ladder; and (B) Representative gel picture of 
SLC6A3rs393795 polymorphism, PCR-RFLP Product checked on 
Gel electrophoresis, Enzyme used Bts I. Lane 1 – Undigested 
PCR product, Lanes 2,6,10 - Homozygous wild (G/G - 348 bp, 
237 bp), Lanes-3, 4, 11, 12 - Heterozygous (G/T - 585 bp, 348 bp, 
237 bp), Lanes- 5, 7, 8, 9 - homozygous mutants (T/T - 585 bp) 
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Genotyping of intronic variant SLC 6A3 G/T (rs393795)  
The genotyping of intronic variant G/T (rs393795) 
polymorphism was done using the PCR RFLP method 
using the following primers for PCR amplification. (i) 
Forward: 5-GCATGTGGAACATTCACCAG -3. (ii) 
Reverse: 5- CAGCCAGCCTTCCTGCAT-3. The 
PCR reaction mixture was setup at 95C initial 
denaturation for 5 min, followed by 38 cycles at 95C 
for 30 sec, 60.2C for 30 sec, and 72C for 30 sec, 
and then a final extension at 72C for 10 min. The 
PCR amplification results in 585 bp length amplicons 
which is subjected to restriction digestion with Bts I 
enzyme (New England Biolabs, MA, USA) at 55C 
for 60 min. Fragments of 348 and 237 bp correspond 
to for the wild G/G genotype, whereas, 585 bp 
undigested product corresponds for mutant T/T 
genotype and 348, 237, 585 fragments correspond for 
the G/T genotype. These were separated by 2% 
agarose gel electrophoresis and were visualized  
using an ultraviolet transilluminator for genotyping 
(Fig. 3B). 
 
Clinical assessment 
MoCA: Montreal Cognitive Assessment (Range:  
0-30, ≥26 normal, <26 impaired cognition). H & Y 
stage: PD severity was determined by modified H & 
Y staging (0-5, 5 is severe). S & E: Schwab and 
England activities of daily living scale (100-0% 
disability).UPDRS III: Unified Parkinson’s disease 
rating scale III clinician-scored monitored motor 
evaluation. aLR: absolute levodopa response 
measured as change in UPDRS III (OFF-ON). PDQ 
39: Parkinson’s disease questionnaire (higher the 
score, worse will be the quality of life). 
 
Statistical analysis 
Genotype frequencies were tested for the deviation 
from Hardy–Weinberg equilibrium using chi square 
(χ2) test (SLC6A3 40 bp VNTR - P =0.69; SLC6A3 
rs393795 - P =0.59). Simple gene counting was 
performed to find out the allele and genotype 
frequency distributions. GraphPad Prism Software 5.0 
(San Diego, USA) was used for generating bar 
graphs. Statistical significance for all the tests were 
considered if the P value is <0.05. 
 
Results 
Demographic characteristics of PD patients 
The demographic characteristics of PD patients are 
shown in (Table 1). There were 106 male and 44 were 
female patients. The age of the male patients and 
female patients were 58.52 ± 9.80 years and 57.00 ± 
10.24 years, respectively. The age of late onset PD 
(>50 years) (LOPD) patients is 64.32 ± 0.66 years, 
which was significantly high (P =<0.0001) compared 
to early onset PD (<50 years) (EOPD) patients i.e., 
49.89 ± 0.99 years. The disease duration was  
6.18 ± 3.40 years. The disease duration was 
significantly higher in EOPD cases (7.18 ± 0.51 
years) compared to LOPD cases (5.40 ± 0.29 years) 
(P =0.002). The disease duration was higher in male 
patients as compared to females (Male: 6.51 ± 2.53 
years, female: 5.40 ± 3.29 years, P =0.07). The 
clinical diagnostic parameters such as the mean 
disease severity by modified H & Y stage, cognitive 
assessment by MoCA, a motor performance by 
UPDRS III OFF and ON scores were recorded at the 
baseline. The mean of disease severity i.e., modified 
H & Y stage was 2.50 ± 0.77, which was not different 
between the EOPD-LOPD groups, male and female 
groups. The mean cognitive assessment score MoCA 
was 28.06 ± 3.40, there is no significant difference 
between male and female EOPD and LOPD groups. 
The mean motor performance - UPDRS III  
‘OFF’ score was 50.49 ± 11.82 and ‘ON’ score was 
17.42 ± 7.20, and the side effect of levodopa therapy 
i.e., dyskinesia score was found significantly higher in 
male patients 1.60 ± 1.16 (P =0.02) compared to 
female patients 1.13 ± 1.01. The pharmacokinetic 
parameter i.e., AUC of levodopa was found significantly 
higher in females 1810.92 ± 1390.77 ng/mL/h  
(P =0.04) compared to males i.e., 1418.43 ± 958.60 
ng/mL/h, whereas it could not reach significance with 
EOPD and LOPD groups (Table 1).  
 
Genotype and allele distribution of SLC6A3polymorphisms 
The genotype distribution of SLC6A3 40 bp VNTR 
polymorphism shows a higher frequency of 10/10 
repeat genotype with 42.6% genotypic distribution, 
followed by 9/10 repeats with 28% genotype 
distribution, and 9/9 repeat with 24%. The frequency 
of 10 repeat-allele was 56%, 9 repeat-allele frequency 
was 38% (Table 2). For the SLC6A3 intronic variant 
rs393795 polymorphism, the frequencies of GG, GT, 
and TT genotype were 38%, 49% and 19%, 
respectively. The allelic frequency of G-allele was 
63% and T-allele was 37% (Table 2). 
 
Association of Pharmacokinetics of Levodopa with genotypes 
As shown in (Table 3), AUC of levodopa was 
significantly higher in patients with SLC6A3 40 bp 
VNTR homozygous 10 repeat (10/10: 1744 ± 147.50  
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Table 1 — Demographic characteristics of Parkinson’s disease patients 
 Parameter Mean ± SD P value 
1. Age (years) (n= 150) 58 ± 10 
0.39  Male (n=106) 58.5 ± 9.8 
 Female (n=44) 57 ± 10.2 
 EOPD (N=65) 49.8 ± 0.9 
<0.0001* 
 LOPD (N=85) 64.3 ±0.6 
2. Age at onset (Years) 51.9 ± 10.1 
0.80  Male 52 ± 10.2 
 Female 51.6 ± 9.6 
 EOPD (n=65) 42.7 ±0.8 
<0.0001* 
 LOPD(n=85) 58.8 ±0.6 
3. PDD (Years) 6.1 ± 3.4 
00.07  Male 6.5 ± 2.5 
 Female 5.4 ± 3.2 
 EOPD (n=65) 7.1 ± 0.5 
0.002* 
 LOPD (n=85) 5.4 ± 0.2 
4. aLR (n= 150) 33.5 ± 10.9 
0.50  Male 33.1 ± 10.5 
 Female 31.8 ± 11.6 
 EOPD 35.6 ± 1.3 
0.02* 
 LOPD 31.6 ± 1.7 
5. LEDD (mg) 968.2 ± 462.3 
 
6. AUC (ng/mL/h) 1535 ± 1111.4 0.04* 
 Male 1418 ± 958.6  
 Female 1810 ± 1390.7  
 EOPD 1448 ± 127.9 0.40 
 LOPD 1602 ± 128.3  
7. S & E (n= 150) 73.6 ± 1.5  
 Male 73.4 ± 1.2 
0.82 
 Female 74 ± 1.7 
 EOPD 73.4 ± 1.8 
0.89 
 LOPD 73.7 ± 1.2 
8. MoCA (n= 150) 28 ±3.4  
 Male 28.3 ±3.8 
0.05* 
 Female 27.2 ±2.1 
 EOPD 28.5 ±0.6 
0.16 
 LOPD 27.7± 0.2 
9. Dyskinesia 1.4 ± 1.1  
 Male 1.6 ± 1.1 
0.02* 
 Female 1.1 ± 1.01 
 EOPD 1.7 ± 0.1 
0.009* 
 LOPD 1.2 ± 0.1 
10. H & Y (n= 150) 2.5 ± 0.7  
 Male 2.5 ± 0.8 
0.62 
 Female 2.5 ± 0.6 
 EOPD 2.5 ± 0.1 
0.89 
 LOPD 2.5 ± 0.07 
11. UPDRS III OFF (n= 150) 50.4 ± 11.8  
EOPD –Early onset parkinsons disease, LOPD- Late onset parkinsons disease, PDD – Parkinsons disease duration, LED – Levodopa equivalent 
daily dosage, AUC-Area under curve, S&E – Schwab & England activity of daily living, H&Y-Hoehn and Yahr staging, MoCA-Montreal 
Cognitive Assessment scale; P value < 0.05 considered as significant 
 
ng/mL/h, P =0.008) compared with homozygous 9 
repeats (9/9: 1002 ± 10980 ng/mL/h) (Table 3). The 
AUC of levodopa in heterozygous genotype 9/10 
(9/10: 1726 ± 187.10 ng/mL/h, P =0.002) was also 
significantly higher compared with homozygous 9 
repeat (9/9: 1002 ± 10980 ng/mL/h) of SLC6A3 40 bp 
VNTR polymorphism (Table 3). Further the data was  
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segregated into EOPD and LOPD groups based onage 
at onset of PD. As shown in (Table 3), AUC of 
levodopa was significantly higher in EOPD patients 
with SLC6A3 40 bp VNTR homozygous 10 repeat 
(10/10: 1616 ± 207.9 ng/mL/h, P =0.002) as 
compared to EOPD patients carrying homozygous 9 
repeat (9/9: 796.30 ± 113.60 ng/mL/h, P =0.01). 
Similarly, LOPD patients carrying 10/10 (1825.00 ± 
203.00 ng/mL/h, P  
=0.001) had higher AUC as compared to LOPD 
patients carrying homozygous  
9 repeat (9/9: 1121.00± 157.60 ng/mL/h, P =0.02).  
A similar observation was seen with heterozygous 
9/10 repeats as compared to 9/9 homozygous repeats 
in patients with EOPD or LOPD. However, there was  
no significant difference in AUC of levodopa 
withwild and variant genotypes was observed with 
SLC6A3 rs393795 (G/T) (Table 3). The mean AUC 
values, when studied within disease duration groups 
(<10 years and > 10 years – as disease progression 
occurs with the duration as well as levodopa 
absorption in to brain), the homozygous 10 repeat, 
heterozygous 9/10 repeat showed significantly higher 
AUC of levodopa when compared to homozygous  
9 repeat in <10 years disease duration group. 
However, there were no significant differences in 
AUC values of  levodopa of 10/10 (1749 ± 157.3), 9/9 
(1018 ± 118.5), and 9/10 (1762 ± 202.2) genotypes in 
patients with > 10 years disease duration (Table 3).  
Table 2 — Genotype and allele frequencies of SLC6A3 
polymorphisms 
SNP Genotype PD (n=150) Allele  
SLC6A3 40 bp 
VNTR 
All the cases 
(n=150) 
10/10 64 (42.6 %) 10 Allele 170 (56.6 %) 
9/10 42 (28 %) 9 Allele 114 (38 %) 
9/9 36 (24 %) 7 Allele 10 (3.3 %) 
7/7 05 (3.3 %) 5 Allele 06 (2 %) 
5/5 03 (2 %)   
SLC6A3 40 bp 
VNTR 
In EOPD group 
(n=65) 
10/10 25 (38.4 %) 10 Allele 75 (57.6 %) 
9/10 25 (38.4 %) 9 Allele 49 (37.6 %) 
9/9 12 (18.4 %) 7 Allele 04 (3 %) 
7/7 02 (3 %) 5 Allele 02 (1.5 %) 
5/5 01 (1.5 %)   
SLC6A3 40 bp 
VNTR 
In LOPD group 
(n=86) 
10/10 39 (45.3 %) 10 Allele 96 (55.8 %) 
9/10 18 (20.9 %) 9 Allele 66 (38.3 %) 
9/9 24 (27.9 %) 7 Allele 06 (3.4 %) 
7/7 03(3.4 %) 5 Allele 04 (2.3 %) 
5/5 02 (2.3 %)   
SLC6A3 r393795 
(G/T) 
In all the cases 
(n=150) 
G/G 58 (38.6 %) G Allele 189 (63 %) 
G/T 73 (48.6 %) T Allele 111 (37 %) 
T/T 19 (12.6 %)   
SLC6A3 r393795 
(G/T) 
In EOPD 
group(n=65) 
G/G 24 (36.9 %) G Allele 77 (59.2 %) 
G/T 29 (44.6 %) T Allele 53 (40.7 %) 
T/T 12 (18.4 %)   
SLC6A3 r393795 
(G/T) 
In LOPD group 
(n=86) 
G/G 34 (39.5 %) G Allele 113 (65.6 %) 
G/T 45 (52.3 %) T Allele 59 (34.3 %) 
T/T 07 (8.13 %)   
EOPD –Early onset Parkinson’s disease, LOPD –Late onset 
Parkinson’s disease, VNTR –Variable number of tandem repeats. 
Table 3 — Association of AUC of Levodopa with SLC6A3 
polymorphisms 
SNP Genotypes AUC ng/mL/h P value 
SLC6A3 40 bp 
VNTR 
10/10 1744 ± 147.5 
0.0008* 
9/9 1002 ± 109.8 
9/10 1726 ± 187.1 
0.002* 
9/9 1002 ± 109.8 
 
EOPD 10/10 1616 ± 207.9 
0.01* 
EOPD 9/9 796.3 ± 113.6 
LOPD 10/10 1825 ± 203 
0.01* 
LOPD 9/9 1121 ± 157.6 
 
EOPD 9/10 1574 ± 225 
0.02* 
EOPD 9/9 796.3 ± 113.6 
LOPD 9/10 1937 ± 320.8 
0.01* 
LOPD 9/9 1121 ± 157.6 
 <10 Years 10/10 1749 ± 157.3 
0.001* 
 <10 Years 9/9 1018 ± 118.5 
 >10 Years 9/10 1762 ± 202.2 
0.003* 
 >10 Years 9/9 1018 ± 118.5 
SLC6A3 r393795 
(G/T) 
G/G 1624 ± 143.8 
0.35 
G/T 1443 ± 130.8 
G/G 1624 ± 143.8 
0.75 
T/T 1532 ± 265.9 
G/T 1443 ± 130.8 
0.75 
T/T 1532 ± 265.9 
EOPD G/G 1637 ± 149.8 
0.68 
EOPD T/T 1502 ± 326.3 
LOPD G/G 1489 ± 567.4 
0.83 
LOPD T/T 1646 ± 381.4 
<10 Years G/G 1493 ± 137.7 
0.41 
<10 Years T/T 1017 ± 228.5 
>10 Years G/G 1489 ± 567.4 
0.83 
>10 Years T/T 1646 ± 381.9 
P value < 0.05 considered as Significant, * indicates significant 
value,EOPD –Early onset Parkinson’s disease, LOPD –Late onset 
Parkinsons Disease. 
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Association of clinical factors with SLC6A3 polymorphisms 
The disease severity score of PD assessed by 
utilising modified H & Y scale (scale 1-5, a score of 5 
is severe), revealed significantly more severe disease 
in patients with homozygous 10/10 genotype of 
SLC6A3 polymorphism with EOPD group (10/10: 
2.82+0.19) compared to heterozygous 9/10 EOPD 
group (9/10: 2.34 ± 0.14) indicating the disease 
progression and severity with the EOPD 10/10 genotype 
of SLC6A3 40 bp VNTR polymorphism (Table 4). 
Significant higher disease severity with disease duration 
(comparing less than 10 years vs. more than 10 years) 
was observed with homozygous 9/9 genotype of 40 bp 
VNTR and polymorphism rs393795(G>T) G/T 
genotype (Table4). 
 
Correlation of Clinical Factors with Levodopa response 
Absolute levodopa response (aLR) is a measure of 
levodopa response obtained by subtracting the ON 
score of UPDRS III with the OFF UPDRS III score. 
Absolute levodopa response was correlated with 
clinical factors such as age at onset of disease (EOPD 
and LOPD), disease duration and AUC of levodopa. 
The age at onset of PD patients was correlated with 
aLR by genotypes of the SLC6A340 bp VNTR 
polymorphism, where we found a significant negative 
correlation with homozygous 10 repeat genotype  
(r = −0.2757, P =0.02) and homozygous 9/9 repeat 
genotype (r = −0.3598, P =0.03) of SLC6A340 bp 
VNTR polymorphism (Table 6). Another clinical 
parameter, disease duration when correlated with aLR 
by the genotypes, we could find a significant positive 
correlation with homozygous 10 repeat (r =0.27,  
P =0.02), heterozygous 9/10 repeat (r =0.59,  
P =<0.0001) and homozygous 9/9 repeats (r =0.3,  
P =0.02) (Table 6) of SLC6A3 40 bp VNTR 
polymorphism. The motor performance was examined 
by UPDRS III score, which when correlated with 
aLR, shows a significant positive correlation with 
10/10 repeat (r =0.27, P =0.02), 9/10 repeat (r =0.59, 
P =<0.0001) and 9/9 repeats (r =0.3, P =0.02) of 
SLC6A3 40 bp VNTR polymorphism (Table 6). 
Further aLR was correlated with AUC of levodopa 
and found no correlation with 10/10 repeat and 
heterozygous 9/10 repeats of SLC6A3 40 bp VNTR 
polymorphism (10/10: r = −0.14, P =0.26; 9/10:  
r = −0.16, P =0.28) while homozygous 9/9 repeat 
showed positive correlation (r =0.31, P =0.06) with 
AUC of levodopa (Table 6). 
 
 
 
Association of Pharmacokinetics of Levodopa with adverse 
events and Side effects of Levodopa therapy 
The adverse events following levodopa treatment 
were recorded by the interview. The most common 
adverse events observed in 20% of the patients were 
nausea, vomiting, and headache and 6.6% of the 
patients were reported leg cramps The most common 
side effect faced by 78% of the patients was 
dyskinesia. Following long-term therapy of levodopa, 
Table 4 — Association of SLC6A3 polymorphisms  
with disease severity 
SNP Genotypes H & Y Stage P value 
SLC6A3 40 bp VNTR 
10/10 2.66 ± 0.10 
0.14 
9/10 2.43 ± 0.11 
 10/10 2.66 ± 0.10 
0.23 
 9/9 2.47 ± 0.10 
 9/10 2.43 ± 0.11 
0.79 
 9/9 2.47 ± 0.10 
 10/10 EOPD 2.82 ± 0.19 
0.05* 
 9/10 EOPD 2.34 ± 0.14 
 10/10EOPD 2.82 ± 0.19 
0.38 
 9/9EOPD 2.54 ± 0.20 
 10/10 LOPD 2.56 ± 0.11 
0.96 
 9/10 LOPD 2.55 ± 0.19 
 10/10 LOPD 2.56 ± 0.11 
0.48 
 9/9 LOPD 2.43 ± 0.12 
 <10Y DD 10/10 2.61 ± 0.10 
0.13 
 <10Y DD 9/10 2.37 ± 0.12 
 <10Y DD 10/10 2.61 ± 0.10 
0.17 
 <10Y DD 9/9 2.39 ± 0.10 
 <10Y DD 9/10 2.37 ± 0.12 
0.89 
 <10Y DD 9/9 2.39 ± 0.10 
 >10Y DD 10/10 3.16 ± 0.47 
0.81 
 >10Y DD 9/10 3.00 ± 0.40 
 >10Y DD 10/10 3.16 ± 0.47 
0.82 
 >10Y DD 9/9 3.33 ± 0.33 
 >10Y DD 9/10 3.00 ± 0.40 
0.57 
 >10Y DD 9/9 3.33 ± 0.33 
 <10Y DD9/9 2.39 ± 0.10 
0.01* 
 >10Y DD9/9 3.33 ± 0.33 
SLC6A3 r393795 
(G/T) 
G/G 2.75 ± 0.11 
0.008* 
G/T 2.38 ± 0.08 
G/G 2.75 ± 0.11 
0.002* 
T/T 2.65 ± 0.15 
G/T 2.38 ± 0.08 
0.13 
T/T 2.65 ± 0.15 
<10Y DDG/T 2.34 ± 0.07 
0.01* 
 >10 Y DD G/T 3.25 ± 0.47 
DD, Disease Duration; EOPD, Early onset PD; LOPD, Late onset 
PD;Disease severity assessed by modified H & Y stage 
(0-5, 5 is severe disease). 
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patients experienced dyskinesia. The dyskinesia score 
was recorded using the UPDRS IV questionnaire, and 
the total score was correlated with AUC for each 
patient. We could not find a significant association of 
dyskinesia with AUC of levodopa by 10/10, 9/10, 9/9 
genotypes of SLC6A3 40 bp VNTR polymorphisms. 
Similarly, no serious adverse events were noted in the 
present study. 
 
Dopamine transporters and the AUC of Levodopa 
In the present study, we found a significant 
association between the SLC6A3 genotype and the 
AUC of levodopa. SLC6A3 is one of the most 
powerful components to determine the dopamine 
metabolism in the striatum14. In some of the studies, it 
has been suggested that higher baseline levels of 
SLC6A3 expression were observed with patients with 
SLC6A3 rs28363170 10/10 genotypes than patients 
with 9/9, 9/10 and 5/5 genotypes and thus lower 
synaptic dopamine levels (due to greater dopamine 
reuptake)19-22. The situation could be more critical in 
advanced PD where marked degeneration of the 
presynaptic neurons within the striatum is reported. 
Hence, one can postulate that plasma levodopa levels 
may vary depending on the genotypes of SLC6A3 
VNTR polymorphism, where 10/10 genotype may 
exhibit higher plasma levodopa levels (High SLC6A3 
expression with 10/10 genotype leads to higher 
reuptake from synaptic cleft resulting in less levodopa 
absorption across blood brain barrier). To support 
the above observation, we found a significant higher 
plasma levodopa concentration in patients with 10/10 
genotype, suggesting that the higher expression of 
SLC6A3 in the striatum with 10/10 genotype and 
higher reuptake of dopamine may be the mechanism 
involved. 
 
Dopamine transporters and the clinical observations of PD 
We found that SLC6A3 genotypes were not 
associated with disease severity as assessed by the H 
& Y stage. When the data were compared between 
EOPD and LOPD groups, significantly high disease 
severity was observed with homozygous 10/10 
genotype compared to the heterozygous 9/10 
genotype of SLC6A3 polymorphism in EOPD group. 
Further segregation of data into less than 10 years 
disease duration and more than 10 years disease 
duration of PD, significantly higher score of H & Y 
stage was found with the homozygous 9/9 genotype 
with>10 years disease duration compared to 
homozygous 9/9 genotype of <10 years disease 
duration group. A similar finding was noted in 
patients with heterozygous G/T genotype of SLC6A3 
intronic polymorphism. Cognitive assessment in PD 
patients was not associated with genotypes of 
SLC6A3 polymorphisms, but when compared in 
EOPD and LOPD groups, the 10/10 genotype in the 
LOPD group had significantly poorer cognition 
compared to heterozygous 9/10 genotype in the same 
group (Table 5). Significantly poor cognition was 
seen with 7/7 and 5/5 genotypes, but the number of 
cases with these genotypes were small (5 and 2, 
respectively) and hence requires future studies. 
 
Absolute levodopa response and Clinical observations of PD 
The motor symptoms response to levodopa is 
crucial in PD management. Absolute Levodopa 
Response (aLR) correlates well with clinically 
Table 5 — Association of SLC6A3 polymorphisms with cognition
SNP Genotypes MoCA P value 
SLC6A3 40 bp VNTR 10/10 27.98 ± 0.24 
0.001* 
7/7 24.80 ± 1.77 
10/10 27.98 ± 0.24 
0.03* 
5/5 25.33 ± 2.90 
9/10 28.21 ± 0.26 
0.0009* 
7/7 24.80 ± 1.77 
9/10 28.21 ± 0.26 
0.02* 
5/5 25.33 ± 2.90 
9/9 27.89 ± 0.42 
0.02* 
7/7 24.80 ± 1.77 
 10/10 EOPD 28.12 ± 0.39 
0.65 
 10/10 LOPD 27.90 ± 0.30 
 9/10 EOPD 28.28 ± 0.26 
0.75 
 9/10 LOPD 28.11 ± 0.52 
 9/9 EOPD 28.50 ± 0.48 
0.39 
 9/9 LOPD 27.75 ± 0.55 
SLC6A3 r393795 (G/T) G/G 27.59 ± 0.35 
0.21 
G/T 28.10 ± 0.23 
G/G 27.59 ± 0.35 
0.64 
T/T 27.89 ± 0.43 
G/T 28.10 ± 0.23 
0.69 
T/T 27.89 ± 0.43 
 G/G EOPD 28.25 ± 0.38 0.25 
 G/G LOPD 27.33 ± 0.46  
 G/T EOPD 29.00 ± 1.26 0.42 
 G/T LOPD 28.19 ± 0.25  
 T/T OPD 28.08 ± 0.55 0.58 
 T/T LOPD 27.57 ± 0.71  
P value < 0.05 considered as Significant, * indicates significant 
value, DD –Disease Duration, EOPD–Early onset PD, LOPD –
Late onset PD, Cognition was assessed by modified MoCA 
Score(Range: 0-30, ≥26 normal, <26 impaired cognition). 
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relevant variables such as motor symptoms, age at 
onset of PD and disease duration. The present results 
demonstrated that change in the motor UPDRS-III 
score and aLR increases with the increase in disease 
duration. This corroborates results found in the other 
two studies that aLR increases with disease 
duration23,24. 
A study by Lees25, suggests that patients exhibiting 
higher amplitudes of aLR have a high UPDRS III 
OFF score. As discussed earlier OFF motor scores are 
a good representation of substantia Nigra pars 
compacta degeneration. Patients would then require 
an increased levodopa dose administration to manage 
their worsening motor symptoms.  
Correlation of aLR by genotypes would allow a 
more accurate determination of genotype effect on the 
disease state and clinical factors. Our results revealed 
higher aLR with a 10/10 genotype and also the AUC 
was significantly associated with the same genotype. 
Late stage PD is often associated with significant 
levodopa-induced motor complications such as motor 
fluctuations and dyskinesia and may be influenced by 
the AUC of levodopa. Theoretically genotype 
variations should impact these complications. 
However, in a recent study, it was shown that there is 
no difference in dyskinesias among genotypes of 
SLC6A3 polymorphisms26. This is in agreement with 
our finding that SLC6A340 bp VNTR genotypes were 
not associated with dyskinesias.  
 
Discussion 
This is the first study to demonstrate that the 
genotypes of the SLC6A3 gene (40 bp VNTR) and 
intronic variant rs393795 of SLC6A3gene are 
associated with the inter-individual differences in the 
therapeutic response to levodopa and clinical 
observations of PD. As SLC6A3 well known to 
determine the dopamine metabolism in the striatum27and 
Table 6 — Association of absolute levodopa response (aLR) and clinical factors of PD with SLC6A3 Genotypes 
  Genotype Combinations r value P Value 
Disease Duration  aLR vs DD 0.38 <0.0001* 
Overall cases aLR vsDD EOPD 0.37 0.001* 
 aLR vsDD LOPD 0.37 0.0004* 
SLC6A3 40 bp VNTR aLR vsDD 10/10 0.21 0.08 
aLR vs DD 9/10 0.59 <0.0001* 
aLR vs DD 9/9 0.36 0.02* 
SLC6A3 r393795 (G/T) aLR vs DD GG 0.40 0.001* 
aLR vs DD GT 0.33 0.003* 
aLR vs DD TT 0.45 0.05* 
UPDRS III OFF Score  aLR vs UPDRS IIII OFF 0.78 <0.0001* 
Overall cases aLR vs UPDRS IIII OFF EOPD 0.79 <0.0001* 
 aLR vs UPDRS IIII OFF LOPD 0.77 <0.0001* 
SLC6A3 40 bp VNTR aLR vs UPDRS IIII OFF 10/10 0.69 <0.0001* 
aLR vs UPDRS IIII OFF 9/10 0.81 <0.0001* 
aLR vs UPDRS IIII OFF 9/9 0.86 <0.0001* 
SLC6A3 r393795 (G/T) aLR vs UPDRS IIII OFF GG 0.86 <0.0001* 
aLR vs UPDRS IIII OFF GT 0.33 0.003* 
aLR vs UPDRSS IIII OFF TT 0.87 <0.0001* 
Age at Onset Overall Case aLR vs AGE AT ONSET -0.23 0.004* 
 aLR vs AGE AT ONSET EOPD -0.23 0.08 
 aLR vs AGE AT ONSET LOPD -0.15 0.14 
SLC6A3 40 bp VNTR aLR vs AGE AT ONSET 10/10 -0.27 0.02* 
aLR vs AGE AT ONSET 9/10 -0.14 0.35 
aLR vs AGE AT ONSET 9/9 -0.35 0.03* 
SLC6A3 r393795 (G/T) aLR vs AGE AT ONSET GG -0.23 0.07 
aLR vs AGE AT ONSET GT -0.25 0.02* 
aLR vs AGE AT ONSET TT -0.23 0.33 
P value < 0.05 considered as Significant, * indicates significant value, DD- Disease Duration, aLR – Absolute Levodopa response, 
EOPD – Early onset Parkinsons disease, LOPD- Late onset Parkinsons Disease. 
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we observed a significantly higher levodopa exposure in 
patients with homozygous 10 repeat and heterozygous 
9/10 repeat genotypes of SLC6A3 40bp VNTR 
compared with homozygous 9/9 genotype. A 
literature search on SLC6A3 genes with the 
association of levodopa pharmacokinetics did not 
found any publications on the possible association 
ofSLC6A3 genotypes with the levodopa of AUC and 
the association of adverse events in patients with the 
levodopa treatment. SLC6A3 gene variants was studied 
to a lesser extent and investigated in PD as the disease 
risk modifiers for the occurrence of dopaminergic-
related complications (such as hallucinations, 
dyskinesia, and depression)28. In the present study, 
10/10 genotype of SLC6A3 40 bp VNTR 
polymorphism showed higher AUC of levodopa, 
which may contribute to increased risk of dyskinesia 
as observed in the present study (data not shown). We 
also found that the patients carrying SLC6A3 
40VNTR 10/10 genotype were associated with the 
disease severity. A possible association with cognitive 
impairment was also observed in LOPD group with 
10/10 genotype.Our results revealed higher aLR with 
10/10 genotype and also associated with increased 
AUC of levodopa, which is in agreement with the 
previous study that OFF motor scores represents the 
substantia Nigra pars compacta degeneration and 
those patients require more and more levodopa 
administration to manage their worsening 
symptoms25.Hence, the knowledge of SLC6A3 
genotype could help the physician to predict the 
disease severity, non-motor symptoms, and 
risk/benefit balance of therapy and to define the 
levodopa treatment strategy in patients with PD. We 
surmise that the genotype may influence the onset of 
dopaminergic related side effects. In addition to 
genotypes, peptides like neurotensin, environmental 
toxins, and other medications are also have role in 
stability and bioavailability of dopamine in brain29. 
Further to establish the role of genotypes along with 
other factors. 
 
Conclusion 
Our results show that dopamine transporters in 
particularly, SLC6A3 40VNTR 10/10 genotype 
significantly influence levodopa concentrations. There 
was a significant increase in AUC of levodopa in 
patients carrying SLC6A3 40VNTR 10/10 genotype.  
This type of observation was also seen in patients in 
both early-onset and late-onset Parkinson’s disease.  
In addition, SLC6A310/10 genotype was found to be 
significantly associated with disease severity in 
patients with early-onset PD. Patients carrying 
SLC6A3 40VNTR 10/10 genotype was found to have 
higher levodopa exposure, indicating greater 
expression of dopamine transporters, greater reuptake 
of dopamine from the synapse, and thus greater 
exposure to levodopa contributing to the disease 
severity and rapid disease progression. However, 
there was no significant association with dyskinesia 
was observed with SLC6A3 40VNTR 10/10 
genotype. 
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